Systemic metabolic markers and myocardial glucose uptake in type 2 diabetic and coronary artery disease patients treated for 16 weeks with rosiglitazone, a PPARγ agonist

Annals of Medicine

Volumn 46, Issue 1, 2014, Pages 18-23

  Badeau, Robert M ^a   Honka, Miikka Juhani ^a   Lautamäki, Riikka ^a   Stewart, Murray ^b   Kangas, Antti J ^c   Soininen, Pasi ^c,d   Ala Korpela, Mika ^c,d,e,f   Nuutila, Pirjo ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b GLAXOSMITHKLINE   (United States)

^c UNIVERSITY OF OULU   (Finland)

^d UNIVERSITY OF EASTERN FINLAND   (Finland)

^e UNIVERSITY OF BRISTOL   (United Kingdom)

^f OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Glutamine; Lactate; Lipoprotein; Metabolomics; Myocardium; NMR spectroscopy; Positron emission tomography; Rosiglitazone; Type 2 diabetes mellitus

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUTAMINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LACTIC ACID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; ROSIGLITAZONE; SULFONYLUREA;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; GLYCEMIC CONTROL; HEART MUSCLE; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HUMAN; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; LACTATE BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; METABOLOMICS; MIDDLE AGED; MYOCARDIAL GLUCOSE UPTAKE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SHORT COURSE THERAPY; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE;

AGED; BLOOD GLUCOSE; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GLUTAMINE; HUMANS; HYPOGLYCEMIC AGENTS; LACTIC ACID; LIPOPROTEINS; MALE; MIDDLE AGED; MYOCARDIUM; PPAR GAMMA; THIAZOLIDINEDIONES; TIME FACTORS;

EID: 84892695193     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2013.853369     Document Type: Article

References (30)

1. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of healThexamination surveys and epidemiological studies with 370 country-years and 2 7 million participants. Lancet. 2011; 378: 31-40.
2. Ferrannini E. Physiology of glucose homeostasis and insulin therapy in type 1 and type 2 diabetes. Endocrinol Metab Clin North Am. 2012; 41: 25-39.
3. Nolan CJ, Damm P, Prentki M. Type 2 diabetes across generations: from pathophysiology to prevention and management. Lancet. 2011; 378: 169-81.
4. Association AD. Standards of medical care in diabetes-2012. Diabetes Care. 2012; 35(Suppl 1): S11-63.
5. Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, Downes M, et al. PPAR[gamma] signaling and metabolism: the good, the bad and the future. Nat Med. 2013; 99: 557-66.
6. Lopes RD, Dickerson S, Hafl ey G, Burns S, Tourt-Uhlig S, White J, et al. Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct. Am Heart J. 2013; 166: 208-16. e28.
7. Iozzo P. Metabolic toxicity of the heart: insights from molecular imaging. Nutr Metab Cardiovasc Dis. 2010; 20: 147-56.
8. Mki M, Luotolahti M, Nuutila P, Iida H, Voipio-Pulkki L-M, Ruotsalainen U, et al. Glucose uptake in the chronically dysfunctional but viable myocardium. Circulation. 1996; 93: 1658-66.
9. Dutka DP, Pitt M, Pagano D, Mongillo M, Gathercole D, Bonser RS, et al. Myocardial glucose transport and utilization in patients with type 2 diabetes mellitus, left ventricular dysfunction, and coronary artery disease. J Am Coll Cardiol. 2006; 48: 2225-31.
10. Iozzo P, Chareonthaitawee P, Dutka D, Betteridge DJ, Ferrannini E, Camici PG. Independent association of type 2 diabetes and coronary artery disease with myocardial insulin resistance. Diabetes. 2002; 51: 3020-4.
11. Opie LH, Sack MN. Metabolic plasticity and the promotion of cardiac protection in ischemia and ischemic preconditioning. J Mol Cell Cardiol. 2002; 34: 1077-89.
12. Lautam ?ki R, Airaksinen KE, Sepp ?nen M, Toikka J, Luotolahti M, Ball E, et al. Rosiglitazone improves myocardial glucose uptake in patients with type 2 diabetes and coronary artery disease: a 16-week randomized, double-blind, placebo-controlled study. Diabetes. 2005; 54: 2787-94.
13. Wrtz P, Tiainen M, M ?kinen VP, Kangas AJ, Soininen P 13., Saltevo J, et al. Circulating metabolite predictors of glycemia in middle-aged men and women. Diabetes Care. 2012; 35: 1749-56.
14. Nekolla SG, Miethaner C, Nguyen N, Ziegler SI, Schwaiger M. Reproducibility of polar map generation and assessment of defect severity and extent assessment in myocardial perfusion imaging using positron emission tomography. Eur J Nucl Med. 1998; 25: 1313-21.
15. Wang J, Stan ? ?kov ?A, Soininen P, Kangas AJ, Paananen J, Kuusisto J, et al. Lipoprotein subclass profi les in individuals with varying degrees of glucose tolerance: a population-based study of 9399 Finnish men. J Intern Med. 2012; 272: 562-72.
16. Soininen P, Kangas AJ, W ?rtz P, Tukiainen T, Tynkkynen T, Laatikainen R, et al. High-throughput serum NMR metabonomics for cost-eff ective holistic studies on systemic metabolism. Analyst. 2009; 134: 1781-5.
17. W ?rtz P, Soininen P, Kangas AJ, R ?nnemaa T, Lehtim ?ki T, K ?h ?nen M, et al. Branched-chain and aromatic amino acids are predictors of insulin resistance in young adults. Diabetes Care. 2013; 36: 648-55.
18. Wang-Sattler R, Yu Z, Herder C, Messias AC, Floegel A, He Y, et al. Novel biomarkers for pre-diabetes identifi ed by metabolomics. Mol Syst Biol. 2012; 8: 615.
19. Stanley WC. Myocardial lactate metabolism during exercise. Med Sci Sports Exerc. 1991; 23: 920-4.
20. Wisneski JA, Gertz EW, Neese RA, Gruenke LD, Morris DL, Craig JC. Metabolic fate of extracted glucose in normal human myocardium. J Clin Invest. 1985; 76: 1819-27.
21. Clark AJ, Gaddie R, Stewart CP. The anaerobic activity of the isolated frog ' s heart. J Physiol. 1932; 75: 321-31.
22. Rovetto MJ, Lamberton WF, Neely JR. Mechanisms of glycolytic inhibition in ischemic rat hearts. Circ Res. 1975; 37: 742-51.
23. Mizock BA, Falk JL. Lactic acidosis in critical illness. Crit Care Med. 1992; 20: 80-93.
24. Greenfi eld JR, Farooqi IS, Keogh JM, Henning E, Habib AM, Blackwood A, et al. Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects. Am J Clin Nutr. 2009; 89: 106-13.
25. Sacks FM, Campos H. Low-density lipoprotein size and cardiovascular disease: a reappraisal. J Clin Endocrinol Metab. 2003; 88: 4525-32.
26. Brehm A, Pfeiler G, Pacini G, Vierhapper H, Roden M. Relationship between serum lipoprotein ratios and insulin resistance in obesity. Clin Chem. 2004; 50: 2316-22.
27. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia. 2003; 46: 733-49.
28. Deeg MA, Buse JB, Goldberg RB, Kendall DM, Zagar AJ, Jacober SJ, et al. Pioglitazone and rosiglitazone have diff erent eff ects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2007; 30: 2458-64.
29. Francis GA. The complexity of HDL. Biochim Biophys Acta. 2 010; 1801: 1286-93.
30. Howard BV. Lipoprotein metabolism in diabetes mellitus. J Lipid Res. 1987; 28: 613-28.